Skip to main content
RUBICON RESEARCH LIMITED logo

RUBICON RESEARCH LIMITED — Investor Relations & Filings

Ticker · RUBICON ISIN · INE506V01022 LEI · 335800GME6PCQIKP8T34 BSE.NS Manufacturing
Open in API
Filings indexed 116 across all filing types
Latest filing 2026-05-29 Investor Presentation
Country IN India
Listing BSE.NS RUBICON

About RUBICON RESEARCH LIMITED

https://www.rubicon.co.in/

Rubicon Research Limited is a specialty organization focused on formulation development and the commercialization of value-added products. The company leverages proprietary drug delivery technology platforms to develop complex oral solids, liquids, topicals, and sterile dosage forms. Its core business activities encompass contract research and manufacturing services alongside the development of a diverse portfolio of Abbreviated New Drug Applications. The firm operates advanced research and development centers and manufacturing facilities that comply with stringent international regulatory standards. Rubicon Research emphasizes innovation in life cycle management and the enhancement of existing molecules to improve patient compliance and therapeutic outcomes. Its operations provide end-to-end solutions from initial concept and formulation design to commercial-scale production, serving global markets with a focus on high-quality, technology-driven solutions.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 90% confidence The document begins as a formal filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges, and encloses an investor presentation dated May 29, 2026. It contains detailed slides on Q4 FY25-26 financial highlights, consolidated income statement, balance sheet, cash flow statements, performance summary, strategic roadmaps, and company overview, all hallmarks of a full investor presentation. It is not merely an announcement that the presentation is available (which would be RPA) but provides the complete presentation content. Therefore, it is classified as an Investor Presentation.
2026-05-29 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 82% confidence The document is a formal notification to stock exchanges under SEBI LODR Regulations providing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditors’ report and CFO declaration. This is not merely a brief highlights release (ER), nor a full annual report (10-K), nor just an announcement of publication (RPA). It contains substantive financial data and the auditor’s opinion, and it covers periodical reporting (quarter and year-end results). Therefore it best fits the “Interim / Quarterly Report” category (IR). FY 2026
2026-05-29 English
Audited Financial Results for the quarter and year ended March 31, 2026, and recommendation of Dividend
Audit Report / Information Classification · 90% confidence The document is a formal filing under SEBI Listing Regulations 30 and 33 that provides the Board’s approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, accompanied by the full Independent Auditor’s Report from Deloitte Haskins & Sells LLP with an unmodified opinion. It is not a full Annual Report (no MD&A or extensive disclosures), nor merely a brief earnings release or dividend notice, but rather the standalone audit report and audited results. This precisely aligns with the “Audit Report / Information (AR)” category. FY 2026
2026-05-29 English
General Updates
Regulatory Filings Classification · 82% confidence The document is an official regulatory announcement under SEBI LODR Reg 30 notifying stock exchanges and investors of the schedule and dial-in details for an upcoming earnings conference call. It does not contain actual financial results (so it is not an Earnings Release) nor is it a report itself. It is not a transcript, presentation, proxy, or other specified form. It is a routine regulatory filing announcement of an event, so it falls under the general Regulatory Filings category (RNS).
2026-05-25 English
Earnings Conference Call
Regulatory Filings Classification · 9% confidence The document is a notice under SEBI Regulation 30 scheduling an earnings conference call (with dial-in details) to discuss quarterly/year-end results. It contains no financial data or transcript, nor does it itself present earnings figures. It is a regulatory announcement of an upcoming event and does not fit earnings release, transcript, or formal report categories. Therefore it is classified as a miscellaneous regulatory filing (RNS).
2026-05-25 English
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting
Regulatory Filings Classification · 85% confidence The document is a formal intimation to stock exchanges under SEBI Listing Obligations (Regulation 29) notifying a forthcoming board meeting to consider and approve audited financial results and recommend dividends. It does not itself contain financial results, nor is it announcing a management change, proxy solicitation, or publication of a report—it is a regulatory disclosure. Therefore, it best fits the general "Regulatory Filings" category (RNS).
2026-05-22 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.